Sign In
Last checked at 
22 Dec 2016 07:00
Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK
Tel 01865 784980
Fax 08701 671931
22nd December 2016
Physiomics plc
("Physiomics") or ("the Company")
Issue of Options
The Company confirms that it has agreed to issue share options to its directors, as follows:
1. 879,521 share options over ordinary shares in the Company ("Share Options") have been granted to Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21st September this year adjusted for the share consolidation carried out on the 19th December).
2. 1,938,564 share options over ordinary shares in the Company ("Share Options") have been granted to Jim Millen under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21st September this year adjusted for the share consolidation carried out on the 19th December).
The options vest based on a combination of performance and time based criteria and can be exercised within 10 years of the date of grant.
Following this issue, Jim Millen will hold options over 1,938,564 ordinary shares of the Company and Christophe Chassagnole will hold options over 2,258,883 ordinary shares in the Company in accordance with the table below.
In addition, Christophe Chassagnole owns 151,897 ordinary shares (equivalent to 0.27% of the currently issued share capital).
Option holder | # Options | Exercise price(p) | Expiry date |
C Chassagnole | 74,994 | 38.300 | 06-Sep-17 |
56,245 | 15.000 | 18-Dec-18 | |
118,565 | 40.000 | 29-Feb-20 | |
32,331 | 34.000 | 08-Nov-21 | |
129,381 | 13.200 | 11-Feb-23 | |
322,615 | 6.167 | 23-Mar-25 | |
645,231 | 3.500 | 20-Dec-25 | |
879,521 | 2.500 | 21-Dec-26 | |
J Millen | 1,938,564 | 2.500 | 21-Dec-26 |
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
Follow the stocks
